Structure Therapeutics licenses GLP-1 patents to Genentech for $100M upfront

Structure Therapeutics Inc.

Gasherbrum Bio (Structure sub) grants non-exclusive license to Genentech/Roche for CT-996 GLP-1 RA.
Genentech pays $100M one-time non-refundable fee within 30 days; plus low single-digit royalties.
License covers patents distinct from aleniglipron; Structure's own GLP-1/dual agonist programs unaffected.
Either party may terminate for uncured material breach; Gasherbrum can terminate if GNE challenges patents.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Structure Therapeutics Inc. entered into GNE Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd valued at $100 million (effective 2025-12-30).

Action: entry
Agreement: license
Counterparty: Genentech, Inc. and F. Hoffmann-La Roche Ltd
Value: $100 million
Effective: 2025-12-30

Exact text from the filing

On December 30, 2025, Gasherbrum Bio, Inc. ("Gasherbrum"), a wholly-owned subsidiary of Structure Therapeutics Inc. (the "Company"), entered into an agreement (the "GNE Agreement") with Genentech, Inc. ("Genentech") and F. Hoffmann-La Roche Ltd ("Roche" and together with Genentech, "GNE") that was the culmination of discussions initiated by Genentech’s inquiry regarding the availability of a license to certain patents of Gasherbrum

View on SEC.gov

294 material agreements filed in the last 30 days. Browse all material agreements →

Structure Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-000620

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.